Ubs Group Ag Merus N.V. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Merus N.V. stock. As of the latest transaction made, Ubs Group Ag holds 10,784 shares of MRUS stock, worth $535,533. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,784

Previous 8,622 25.08%

Holding current value

$535,533

Previous $510,000 5.49%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$47.19 - $58.84 $102,024 - $127,212	2,162 Added 25.08%	10,784 $538,000
Q2 2024 Aug 13, 2024	BUY	$39.81 - $60.2 $58,600 - $88,614	1,472 Added 20.59%	8,622 $510,000
Q1 2024 May 13, 2024	BUY	$28.03 - $51.82 $44,483 - $82,238	1,587 Added 28.53%	7,150 $321,000
Q4 2023 Feb 09, 2024	BUY	$20.06 - $28.66 $108,925 - $155,623	5,430 Added 4082.71%	5,563 $152,000
Q3 2023 Nov 09, 2023	SELL	$20.13 - $27.29 $40 - $54	-2 Reduced 1.48%	133 $3,000
Q2 2023 Aug 11, 2023	SELL	$18.33 - $27.18 $13,215 - $19,596	-721 Reduced 84.23%	135 $3,000
Q1 2023 May 12, 2023	BUY	$14.25 - $20.5 $10,773 - $15,498	756 Added 756.0%	856 $15,000
Q4 2022 Feb 08, 2023	SELL	$12.8 - $23.66 $186,752 - $345,199	-14,590 Reduced 99.32%	100 $1,000
Q3 2022 Nov 10, 2022	BUY	$18.64 - $28.93 $271,957 - $422,088	14,590 Added 14590.0%	14,690 $294,000
Q2 2022 Aug 10, 2022	SELL	$13.98 - $29.25 $50,775 - $106,236	-3,632 Reduced 97.32%	100 $2,000
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $64,727 - $84,847	2,745 Added 278.12%	3,732 $99,000
Q4 2021 Feb 14, 2022	SELL	$20.0 - $32.29 $46,240 - $74,654	-2,312 Reduced 70.08%	987 $32,000
Q3 2021 Nov 15, 2021	BUY	$16.48 - $27.23 $7,399 - $12,226	449 Added 15.75%	3,299 $72,000
Q2 2021 Aug 13, 2021	SELL	$20.0 - $25.48 $980 - $1,248	-49 Reduced 1.69%	2,850 $60,000
Q1 2021 May 12, 2021	BUY	$16.14 - $29.11 $31,924 - $57,579	1,978 Added 214.77%	2,899 $61,000
Q4 2020 Feb 11, 2021	BUY	$11.4 - $18.36 $376 - $605	33 Added 3.72%	921 $16,000
Q3 2020 Nov 12, 2020	BUY	$10.57 - $16.0 $5,242 - $7,936	496 Added 126.53%	888 $10,000
Q2 2020 Jul 31, 2020	BUY	$10.5 - $17.36 $4,116 - $6,805	392 New	392 $6,000
Q1 2020 May 01, 2020	SELL	$11.34 - $19.44 $23,870 - $40,921	-2,105 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$14.08 - $18.5 $29,638 - $38,942	2,105 New	2,105 $30,000
Q3 2019 Nov 14, 2019	SELL	$14.55 - $20.52 $5,718 - $8,064	-393 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$12.93 - $16.83 $5,081 - $6,614	393 New	393 $6,000
Q1 2019 May 14, 2019	SELL	$11.09 - $15.83 $7,552 - $10,780	-681 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$11.46 - $20.81 $343 - $624	30 Added 4.61%	681 $10,000
Q3 2018 Nov 14, 2018	BUY	$18.47 - $26.39 $2,862 - $4,090	155 Added 31.25%	651 $13,000
Q2 2018 Aug 14, 2018	BUY	$16.77 - $22.76 $8,317 - $11,288	496 New	496 $11,000
Q1 2018 May 15, 2018	SELL	$16.07 - $19.87 $22,224 - $27,480	-1,383 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$14.23 - $21.28 $26,638 - $39,836	-1,872 Reduced 57.51%	1,383 $27,000
Q3 2017 Nov 14, 2017	SELL	$13.6 - $19.87 $26,860 - $39,243	-1,975 Reduced 37.76%	3,255 $65,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,200 Added 17333.33%	5,230 $82,000
Q1 2017 Nov 14, 2017	BUY	N/A	30	30 $1,000

Others Institutions Holding MRUS

# of Institutions

200

Shares Held

61.9M

Call Options Held

243K

Put Options Held

300K

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account